Abstract CT406: Patients with cancer appear more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak

Abstract

The novel COVID-19 outbreak has affected more than 200 countries and territories as of March 2020. Given that patients with cancer are generally more vulnerable to infections, systematic analysis of diverse cohorts of patients with cancer affected by COVID-19 are needed. We performed a multi-center study including 105 cancer patients and 536 age-matched non-cancer patients confirmed with COVID-19. Our results showed COVID-19 patients with cancer had higher risks in all severe outcomes. Patients with hematological cancer, lung cancer, or with metastatic cancer (stage IV) had the highest frequency of severe events. Non-metastatic cancer patients experienced similar frequencies of severe conditions to those observed in patients without cancer. Patients who received surgery had higher risks of having severe events, while patients with only radiotherapy did not demonstrate significant differences in severe events when compared to patients without cancer. These findings indicate that cancer patients appear more vulnerable to SARS-COV-2 outbreak. Since this is the first large cohort study on this topic, our report will provide the much-needed information that will benefit global cancer patients. As such, we believe it is extremely important that our study be disseminated widely to alert clinicians and patients. Citation Format: Meng-Yuan Dai, Dian-bo Liu, Miao Liu, Fu-Xiang Zhou, Gui-Ling Li, Zhen Chen, Zhi-An Zhang, Hua-You Md, Meng Wu, Qi-Chao Zheng, Yong Xiong, Hui-Hua Xiong, Chun Wang, Chang-Chun Chen, Fei Xiong, Yan Zhang, Ya-Qin Peng, Si-Ping Ge, Bo Zhen, Ting-Ting Yu, Ling Wang, Hua Wang, Yu Liu, Ye-Shan Chen, Jun-Hua Mei, Xiao-Jia Gao, Zhu-Yan Li, Li-Juan Gan, Can He, Zhen Li, Yu-Ying Shi, Yu-Wen Qi, Jing Yang, Daniel G. Tenen, Li Chai, Lorelei Ann Mucci, Mauricio Santillana, Hongbing Cai. Patients with cancer appear more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT406.

Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes

“…A study conducted at Memorial Sloan Kettering Cancer Center (MSKCC) reported that among 102 lung cancer patients having COVID-19, 62 patients developed severe symptoms, and 25 patients died with aggravated respiratory disorders [ 40 ]. Similar studies have also confirmed that lung cancer patients are at high risk in developing severe symptoms due to SARS-CoV2 infection and simultaneous ineffectiveness of the chemotherapeutic regime [ 41 , 42 ]. Individuals suffering from lung cancer generally have impaired alveolar function with upregulated expression of ACE2 receptor, immunosuppressive cytokines, and impaired function of cytotoxic immune cells [ 43 , 44 ].…”

Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran

“…Some studies have reported that patients with cancer have an increased risk of contracting COVID-19. 21 , 22 , 23 Our study is the first report of COVID-19 in children with cancer referred to a cancer center in Iran. During the period of our study, 17 of 637 patients contracted COVID-19, according to our institutional criteria,.…”

Таргетна Терапія Недрібноклітинного Раку Легені З Рідкісними Мутаціями Гена EGFR

“…Втім, питанню лікування пацієнтів із НДРЛ від основного захворювання у випадку їх інфікування COVID-19 присвячено значно менше уваги. При цьому для пацієнтів із злоякісними новоутвореннями, особливо із РЛ, характерний значно тяжчий перебіг COVID-19, включаючи вищі показники госпіталізації та смертності порівняно із загальною популяцією [58][59][60][61]. Так, у пацієнтів із COVID-19, хворих на рак, ризик тяжкого перебігу захворювання вищий в усіх випадках.…”

“…Пацієнти, які перенесли операцію, мали більш високий ризик тяжкого перебігу захворювання, тоді як пацієнти, які проходили лише променеву терапію, не продемонстрували суттєвих відмінностей щодо ризику тяжкого перебігу порівняно з пацієнтами без раку. Ці результати вказують на те, що пацієнти з раком виявляються більш вразливими до спалаху SARS-CoV-2 [58]. Загалом пацієнти з РЛ мають вищий ризик смертності від COVID-19, ніж хворі загальної популяції [62].…”